Poly Medicure’s board approved the unaudited financial results for Q3 (Oct-Dec) and nine months ending December 31, 2025. The Nomination & Remuneration Committee also approved a grant of 2,000 stock options under the Employee Stock Option Scheme 2020 to eligible employees. The board meeting, held on February 5, 2026, also addressed other business items.
Q3 Financial Results Approved
The Board of Directors has approved the unaudited financial results (Consolidated & Standalone) for the third quarter and nine months ended December 31, 2025.
Details of Standalone Performance
The company reported total income of ₹1,32,424.57 lacs for the nine months ended December 31, 2025, compared to ₹1,24,665.42 lacs for the same period last year. Profit after tax stood at ₹25,536.32 lacs, against ₹24,467.45 lacs in the previous year. Basic earnings per share stood at ₹25.20 and diluted earnings per share stood at ₹25.17.
Consolidated Financial Highlights
The consolidated results show total income of ₹1,44,307.35 lacs for the nine months ended December 31, 2025, compared to ₹1,29,382.15 lacs for the same period last year. Profit after tax for the nine months amounted to ₹25,568.90 lacs, versus ₹24,672.30 lacs in the previous year. Basic earnings per share were ₹25.25 and diluted earnings per share were ₹25.22.
ESOP Grant Approved
The Nomination & Remuneration Committee has approved the grant of 2,000 stock options under the Poly Medicure Limited Employee Stock Option Scheme 2020 to eligible employees.
Impact of Labour Codes
The company recognized a provision of ₹680.40 lacs towards past service cost on gratuity and compensated absences due to the notification of the Labour Codes. This is reflected as an exceptional item in the financial results.
Source: BSE
